Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
作者信息
Mistry Pramod K, Balwani Manisha, Baris Hagit N, Turkia Hadhami Ben, Burrow T Andrew, Charrow Joel, Cox Gerald F, Danda Sumita, Dragosky Marta, Drelichman Guillermo, El-Beshlawy Amal, Fraga Cristina, Freisens Selena, Gaemers Sebastiaan, Hadjiev Evgueniy, Kishnani Priya S, Lukina Elena, Maison-Blanche Pierre, Martins Ana Maria, Pastores Gregory, Petakov Milan, Peterschmitt M Judith, Rosenbaum Hanna, Rosenbloom Barry, Underhill Lisa H, Cox Timothy M
机构信息
Yale University School of Medicine, New Haven, CT, USA.
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Blood Cells Mol Dis. 2018 Jul;71:71-74. doi: 10.1016/j.bcmd.2018.04.001. Epub 2018 Apr 9.
PMID:29680197
Abstract
摘要
Zotero 插件